ADVERSE EVENT REPORTING OF MARKETING BIOSIMILAR AND BIOLOGICAL MONOCLONAL ANTIBODY CANCER TREATMENTS

被引：0
|
作者：
Xue, X. Xiangzhong [1 ]
Qian, J. [1 ]
机构：
[1] Auburn Univ, Harrison Coll Pharm, Auburn, AL USA
来源：
RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY | 2023年 / 19卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：564 / 564
页数：1
相关论文
共 50 条
  • [21] Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
    Shu, Yamin
    Ding, Yufeng
    Liu, Yanxin
    Wu, Pan
    He, Xucheng
    Zhang, Qilin
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [22] Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system
    Wu, Xiang-Ping
    Lu, Xi-Kui
    Wang, Zhen-Ting
    Huang, Ling
    Cai, Ru-Wen
    Yu, Hui-Min
    Li, Jing-Yang
    Xiao, Jian
    [J]. EXPERT OPINION ON DRUG SAFETY, 2023, : 975 - 984
  • [23] Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system
    Xia, Chunyong
    Liu, Zhijing
    Liu, Jie
    Lin, Li
    Chen, Maohua
    [J]. INVESTIGATIONAL NEW DRUGS, 2024,
  • [24] Biological impediments to monoclonal antibody-based cancer immunotherapy
    Christiansen, J
    Rajasekaran, AK
    [J]. MOLECULAR CANCER THERAPEUTICS, 2004, 3 (11) : 1493 - 1501
  • [25] The Adverse Event Expedited Reporting System (AdEERS) of the cancer therapy evaluation program
    Shoemaker, D
    Setser, A
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 : S64 - S64
  • [26] Geographic variation in adverse event reporting patterns in breast cancer clinical trials
    Gonzalez, Valeria
    Machado, Andres
    Fung, Helena
    Spera, Gonzalo
    Meyer, Carlos
    Millan, Pablo
    Mackey, John R.
    Fresco, Rodrigo
    [J]. CANCER RESEARCH, 2018, 78 (04)
  • [27] Adverse event reporting in publications compared with sponsor database for cancer clinical trials
    Scharf, Orit
    Colevas, A. Dimitrios
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) : 3933 - 3938
  • [28] Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system
    Sun, Wenfang
    Li, Yali
    Xia, Binbin
    Chen, Jing
    Liu, Yang
    Pang, Jingyao
    Liu, Fang
    Cheng, Hua
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 14
  • [29] Post-marketing safety concerns with montelukast: A pharmacovigilance study based on the FDA adverse event reporting system
    Ou, Zhimin
    Han, Ying
    Zhuang, Wei
    Xiao, Yunshan
    Cai, Shuying
    Zhang, Xueqin
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2024,
  • [30] Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
    Xiong, Rui
    Lei, Jing
    Pan, Sicen
    Zhang, Hong
    Tong, Yongtao
    Wu, Wei
    Huang, Yi
    Lai, Xiaodan
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
12345